Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cantwell B. M., Harris A. L. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer. Br Med J (Clin Res Ed) 1987 Feb 21;294(6570):467–469. doi: 10.1136/bmj.294.6570.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Elomaa I., Blomqvist C., Gröhn P., Porkka L., Kairento A. L., Selander K., Lamberg-Allardt C., Holmström T. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet. 1983 Jan 22;1(8317):146–149. doi: 10.1016/s0140-6736(83)92755-1. [DOI] [PubMed] [Google Scholar]
- Fogelman I., Smith L., Mazess R., Wilson M. A., Bevan J. A. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol (Oxf) 1986 Jan;24(1):57–62. doi: 10.1111/j.1365-2265.1986.tb03254.x. [DOI] [PubMed] [Google Scholar]
- Morton A. R., Cantrill J. A., Craig A. E., Howell A., Davies M., Anderson D. C. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. Br Med J (Clin Res Ed) 1988 Mar 19;296(6625):811–814. doi: 10.1136/bmj.296.6625.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morton A. R., Cantrill J. A., Pillai G. V., McMahon A., Anderson D. C., Howell A. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ. 1988 Sep 24;297(6651):772–773. doi: 10.1136/bmj.297.6651.772. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Plasmans C. M., Jap P. H., Kuijpers W., Slooff T. J. Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Int. 1980;32(3):247–266. doi: 10.1007/BF02408548. [DOI] [PubMed] [Google Scholar]
- Robertson W. G., Morgan D. B., Fleisch H., Francis M. D. The effects of diphosphonates on the exchangeable and non-exchangeable calcium and phosphate of hydroxyapatite. Biochim Biophys Acta. 1971 Feb 28;261(2):517–525. doi: 10.1016/0304-4165(72)90076-1. [DOI] [PubMed] [Google Scholar]
- Shinoda H., Adamek G., Felix R., Fleisch H., Schenk R., Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int. 1983;35(1):87–99. doi: 10.1007/BF02405012. [DOI] [PubMed] [Google Scholar]
- Thiébaud D., Jaeger P., Jacquet A. F., Burckhardt P. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol. 1988 May;6(5):762–768. doi: 10.1200/JCO.1988.6.5.762. [DOI] [PubMed] [Google Scholar]
- van Holten-Verzantvoort A. T., Bijvoet O. L., Cleton F. J., Hermans J., Kroon H. M., Harinck H. I., Vermey P., Elte J. W., Neijt J. P., Beex L. V. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet. 1987 Oct 31;2(8566):983–985. doi: 10.1016/s0140-6736(87)92555-4. [DOI] [PubMed] [Google Scholar]